Aberrant expression of EZH2 is associated with pathological findings and P53 alteration

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4309-4317

  Shiogama, Sunao ^a   Yoshiba, Sayaka ^a   Soga, Daisuke ^a   Motohashi, Hiromi ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

BMI1; EZH2; Human oral squamous cell carcinoma; p53

Indexed keywords

BMI1 PROTEIN; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR INVASION; UPREGULATION; VERY ELDERLY;

BMI1; EZH2; HUMAN ORAL SQUAMOUS CELL CARCINOMA; P53;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 1; POLYCOMB REPRESSIVE COMPLEX 2; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84891355810     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Barnes L, Eveson JW, Reichart P and Sidransky D: WHO: Pathology and Genetics of Head and Neck Tumors. IARC Press: Lyon, 168, 2005.
2. Pirrotta V: Polycomb silencing and the maintenance of stable chromatin states. Resultu Probl Cell Differ 25: 205-228, 1999.
3. Bardos JI, Saurin AJ, Tissot C, Duprez E and Freemont PS: HPC3 is a new human polycomb orthologue that interacts and associates with RING1 and BMI1 and has transcriptional repression properties. J Biol Chem 275: 28785-28792, 2000.
4. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA and Chinnaiyan AM: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
5. Kleer CG, Cao Q, Varambally S, Shen R, Ota I and Tomlins SA. Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA and Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606-11611, 2003.
6. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TLJ and Visakorpi T: EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122: 595-602.
7. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP and Akslen LA: Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-1174, 2006.
8. Mimori K, Ogawa K, Okamoto T, Sudo T, Inoue H and Mori M: Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31: 376-380, 2005.
9. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K and Yokozaki H: Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97: 484-491, 2006.
10. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K and Ito H: High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45: 39-46, 2009.
11. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E and Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323-5335, 2003.
12. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N and Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23: 5759-5769, 2004.
13. Croonquist PA and van Ness B: The polycomb group protein enhancer of zeste analog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24: 6269-6280, 2005.
14. Bryant RJ, Cross NA, Eaton CL, Hamdy FC and Cunliffe VT: EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67: 547-556, 2007.
15. Visser HPJ, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, Willemze R and Otte AP: The polycomb group protein EZH2 is up-regulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112: 950-958, 2001.
16. Chen H, Tu SW and Hsieh JT: Down-regulation of human DAB2IP gene expression mediated by polycomb EZH2 complex and histone deacetylase in prostate cancer. J Biol Chem 280: 22437-22444, 2005.
17. Fujii S and Ochiai A: Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric carcinoma cells. Cancer Sci 99: 738-746, 2008.
18. Fujii S, Ito K, Ito Y and Ochiai A: Enhencer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283: 17324-17332, 2008.
19. Spivakov M and Fisher AG: Epigenetic signatures of stem-cell identify. Nat Rev Genet 8: 263-271, 2007.
20. Arf senescence pathways. Genes Dev 19: 1432-1437, 2005.
21. Kang MK, Kim RH, Kim SJ, Yip FK, Shin KH, Dimri GP, Christensen R, Han T and Park NH: Elevated BMI-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 96: 126-133, 2007.
22. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, Fu LW, Huang WL, Dimri GP, Band V and Zeng YX: BMI-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232, 2006.
23. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS and Kim JW: Overexpression of BMI-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13: 383, 2004.
24. Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Haung W, Song HF, Chen MS and Xia JC: Increased polycomb group oncogene BMI-1 expresion correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541, 2008.
25. Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M and Marino S: BMI1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428: 337-341, 2004.
26. Häyry V, Tynninen O, Haapasalo HK, Wölfer J, Paulus W, Hasselblatt M, Sariola H, Paetau A, Sarma S, Niemelä M, Wartiovaara K and Nupponen NN: Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol 34: 555-563, 2008.
27. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, Knizetova P, Hajduch M, Klein J, Kolek V, Radova L and Kolar Z: Prognostic value of BMI-1 oncoprotein expression in NSCLC patients: A tissue microarray study. J Cancer Res Clin Oncol 134: 1037-1042, 2008.
28. Hamilton SR and Aatonen LA (eds.): World Health Organization Classification of Tumors of the Digestive System. IARC Press, Lyon, pp. 11-19, 2000.
29. Yasuda M, Kuwano H, Watanabe M, Toh Y, Ohno S and Sugimachi K: P53 expression in squamous dysplasia associated with carcinoma of the esophagus: Evidence for field carcinogenesis. Br J Cancer 83: 1033-1038, 2000.
30. Egashira A, Morita M, Kakeji K, Kurahashi T, Ito H, Kumekawa Y, Yamamoto T, Muramoto T, Kubota Y, Nozawa H, Makino R, Kushima M and Imawari M: Study of P53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus. Br J Cancer 96: 492-498, 2007.
31. Foco F, Bilalović N, Vranić S, Serdarević F, Ramović I and Imamović E: Peritumoral P53 expression in oral carcinoma. Coll Antropol; Nov 36(Suppl 2): 129-32, 2012.
32. Sarkar J, Dominguez E, Li G, Kusewitt DF and Johnson DG: Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the P53 R72P polymorphism in modulating susceptibility. Mol Carcinog.
33. Francis G, Dileep KU, Nalinakumari KR, Jayasree K and Kannan S: Accumulation of inactive P53 protein in oral squamous cell carcinoma: Stabilization by protein interaction. Eur J Oral Sci 121(1): 21-28, 2013.
34. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, MöLLer P, Stilqenbauer S, Pollack JR and Wirth T: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112: 4202-4212, 2008.
35. Wong CF and Tellam RL: MicroRNA-26a targets the histone methyltransferase enhancer of zeste homolog 2 during myogenesis. J Biol Chem 283: 9836-9843, 2008.
36. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Loniqro RJ, Palanisamy N, Maher CA and Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-1699, 2008.
37. Pietersen AM, Horlings HM, Hauptmann M, Langercd A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ and van Lohuizen M: EZH2 and BMI1 inversely correlated with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10: R109, 2008.
38. Sobin LH and Fleming ID: TNM Clssification of Malignant Tumors, Fifth Edition. Union International Contre le Cancer and the American Joint Committee on Cancer. Cancer 80: 1803-1804, 1997.
39. Wasi PN, Cohen B, Luthra UK and Torloni H: Histological Typing of Oral and Oropharyngeal Tumors, International Histological Classification of Tumor. Geneva, WHO; pp. 17-18, 1971.
40. Anneroth G, Batsakis J and Lunba M: Review of the literature and a recommended system of malignancy grading in oral squaomous cell carcinomas. Scand J Dent Res 95: 229-249, 1987.
41. Ohnishi K, Ota I, Takahashi A and Ohnishi T: Glycerol restores P53-dependent radiosensitivity of human head and neck cancer cells bearing mutant P53. BJ Cancer 83 (12): 1735-1739, 2000.
42. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, Chen YC, Zhang LJ, Guan XY, Zeng YX, Kung HF and Xie D: High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 127: 138-147, 2010.